Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test

The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo’s Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples

See more here